
A biopharmaceutical company reaches 65+ aligned investors.
The challenge
Raising a $5M seed round, the company needed targeted investor access beyond its own network.
What we built
- Strategic investor targeting across specialist investor networks
- Compelling positioning and narrative
- Pipeline management and facilitation
The outcome
Within four months, 65+ aligned investors, a lead investor secured and multiple groups in due diligence.






























